Fibrodysplasia Ossificans Progressiva Differential Diagnoses

1. Pignolo RJ, Baujat G, Brown MA, De Cunto C, DiRocco M, Hsiao EC, et al. Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes. Orphanet J Rare Dis. 2019 May 3. 14 (1):98. [QxMD MEDLINE Link].

2. Pignolo RJ, Baujat G, Brown MA, De Cunto C, Di Rocco M, Hsiao EC, et al. Correction to: Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes. Orphanet J Rare Dis. 2019 May 23. 14 (1):113. [QxMD MEDLINE Link].

3. Kaplan FS, Zasloff MA, Kitterman JA, Shore EM, Hong CC, Rocke DM. Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am. 2010 Mar. 92(3):686-91. [QxMD MEDLINE Link]. [Full Text].

4. Muthu V, Khaire NS, Varma S. Fibrodysplasia ossificans progressiva-primum non nocere. Clin Rheumatol. 2014 Apr. 33(4):591-2. [QxMD MEDLINE Link].

5. Feldman G, Li M, Martin S, et al. Fibrodysplasia ossificans progressiva, a heritable disorder of severe heterotopic ossification, maps to human chromosome 4q27-31. Am J Hum Genet. 2000 Jan. 66(1):128-35. [QxMD MEDLINE Link].

6. de la Pena LS, Billings PC, Fiori JL, Ahn J, Kaplan FS, Shore EM. Fibrodysplasia ossificans progressiva (FOP), a disorder of ectopic osteogenesis, misregulates cell surface expression and trafficking of BMPRIA. J Bone Miner Res. 2005 Jul. 20(7):1168-76. [QxMD MEDLINE Link].

7. Shore EM, Glaser DL, Gannon FH. Osteogenic induction in hereditary disorders of heterotopic ossification. Clin Orthop Relat Res. 2000 May. 303-16. [QxMD MEDLINE Link].

8. Shore EM, Xu M, Feldman GJ, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006 May. 38(5):525-7. [QxMD MEDLINE Link].

9. Fontaine K, Semonin O, Legarde JP, Lenoir G, Lucotte G. A new mutation of the noggin gene in a French Fibrodysplasia ossificans progressiva (FOP) family. Genet Couns. 2005. 16(2):149-54. [QxMD MEDLINE Link].

10. Nakajima M, Haga N, Takikawa K, Manabe N, Nishimura G, Ikegawa S. The ACVR1 617G>A mutation is also recurrent in three Japanese patients with fibrodysplasia ossificans progressiva. J Hum Genet. 2007. 52(5):473-5. [QxMD MEDLINE Link].

11. Furuya H, Ikezoe K, Wang L, et al. A unique case of fibrodysplasia ossificans progressiva with an ACVR1 mutation, G356D, other than the common mutation (R206H). Am J Med Genet A. 2008 Feb 15. 146A(4):459-63. [QxMD MEDLINE Link].

12. Kaplan FS, Xu M, Seemann P, et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat. 2009 Mar. 30(3):379-90. [QxMD MEDLINE Link].

13. Petrie KA, Lee WH, Bullock AN, et al. Novel mutations in ACVR1 result in atypical features in two fibrodysplasia ossificans progressiva patients. PLoS One. 2009. 4(3):e5005. [QxMD MEDLINE Link]. [Full Text].

14. Nakahara Y, Katagiri T, Ogata N, Haga N. ACVR1 (587T>C) mutation in a variant form of fibrodysplasia ossificans progressiva: second report. Am J Med Genet A. 2014 Jan. 164A(1):220-4. [QxMD MEDLINE Link].

15. Song GA, Kim HJ, Woo KM, Baek JH, Kim GS, Choi JY, et al. Molecular consequences of the ACVR1 R206H mutation of fibrodysplasia ossificans progressiva. J Biol Chem. 2010 May 12. [QxMD MEDLINE Link].

16. Herrera-Esparza R, Pacheco-Tovar D, Bollain-Y-Goytia JJ, Torres Del Muro F, Ramírez-Sandoval R, Pacheco-Tovar MG, et al. An Activin Receptor IA/Activin-Like Kinase-2 (R206H) Mutation in Fibrodysplasia Ossificans Progressiva. Case Rep Genet. 2013. 2013:260371. [QxMD MEDLINE Link]. [Full Text].

17. Baujat G, Choquet R, Bouée S, Jeanbat V, Courouve L, Ruel A, et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases. Orphanet J Rare Dis. 2017 Jun 30. 12 (1):123. [QxMD MEDLINE Link].

18. Haga N, Nakashima Y, Kitoh H, Kamizono J, Katagiri T, Saijo H, et al. Fibrodysplasia Ossificans Progressiva: Review and Research Activities in Japan. Pediatr Int. 2019 Nov 27. [QxMD MEDLINE Link].

19. Lin FY, Lin CH, Shu G, Chen CK. Fibrodysplasia ossificans progressiva: initial presentation with a preosseous lesion of the scalp and its MRI appearance. Skeletal Radiol. 2016 Jul. 45 (7):991-6. [QxMD MEDLINE Link].

20. Pignolo RJ, Bedford-Gay C, Liljesthröm M, Durbin-Johnson BP, Shore EM, Rocke DM, et al. The Natural History of Flare-Ups in Fibrodysplasia Ossificans Progressiva (FOP): A Comprehensive Global Assessment. J Bone Miner Res. 2016 Mar. 31 (3):650-6. [QxMD MEDLINE Link].

21. Kitterman JA, Strober JB, Kan L, Rocke DM, Cali A, Peeper J, et al. Neurological symptoms in individuals with fibrodysplasia ossificans progressiva. J Neurol. 2012 Dec. 259(12):2636-43. [QxMD MEDLINE Link]. [Full Text].

22. Towler OW, Shore EM, Kaplan FS. Skeletal malformations and developmental arthropathy in individuals who have fibrodysplasia ossificans progressiva. Bone. 2020 Jan. 130:115116. [QxMD MEDLINE Link].

23. Kriegbaum RK, Hillerup S. Fibrodysplasia ossificans progressiva (FOP): Report of a case with extra-articular ankylosis of the mandible. J Craniomaxillofac Surg. 2013 Mar 16. [QxMD MEDLINE Link].

24. Deirmengian GK, Hebela NM, O'Connell M, Glaser DL, Shore EM, Kaplan FS. Proximal tibial osteochondromas in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am. 2008 Feb. 90(2):366-74. [QxMD MEDLINE Link].

25. Chichareon V, Arpornmaeklong P, Donsakul N. Fibrodysplasia ossificans progressiva and associated osteochondroma of the coronoid process in a child. Plast Reconstr Surg. 1999 Apr. 103(4):1238-43. [QxMD MEDLINE Link].

26. Levy CE, Lash AT, Janoff HB, Kaplan FS. Conductive hearing loss in individuals with fibrodysplasia ossificans progressiva. Am J Audiol. 1999 Jun. 8(1):29-33. [QxMD MEDLINE Link].

27. Aslan G, Celik F, Gorgu M. Unusual ankylosis of the jaw due to fibrodysplasia ossificans progressiva. Ann Plast Surg. 1999 Nov. 43(5):576-8. [QxMD MEDLINE Link].

28. van der Meij EH, Becking AG, van der Waal I. Fibrodysplasia ossificans progressiva. An unusual cause of restricted mandibular movement. Oral Dis. 2006 Mar. 12(2):204-7. [QxMD MEDLINE Link].

29. Jeziorska M, Dabska M, Buraczewski J. [Myositis ossificans (clinico-pathological entity often diagnosed erroneously as malignant tumor)]. Nowotwory. 1980 Apr-Jun. 30(2):183-94. [QxMD MEDLINE Link].

30. Pignolo RJ, McCarrick-Walmsley R, Wang H, et al. Plasma-Soluble Biomarkers for Fibrodysplasia Ossificans Progressiva (FOP) Reflect Acute and Chronic Inflammatory States. J Bone Miner Res. 2022 Mar. 37 (3):475-483. [QxMD MEDLINE Link].

31. Zaghloul KA, Heuer GG, Guttenberg MD, Shore EM, Kaplan FS, Storm PB. Lumbar puncture and surgical intervention in a child with undiagnosed fibrodysplasia ossificans progressiva. J Neurosurg Pediatr. 2008 Jan. 1(1):91-4. [QxMD MEDLINE Link].

32. Chuang TL, Ho KW, Wang YF. A Bizarre Bone Scan of Fibrodysplasia Ossificans Progressiva. Clin Nucl Med. 2018 Jun. 43 (6):433-435. [QxMD MEDLINE Link].

33. Carvalho DR, Farage L, Martins BJ, Speck-Martins CE. Craniofacial findings in fibrodysplasia ossificans progressiva: computerized tomography evaluation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Apr. 111(4):499-502. [QxMD MEDLINE Link].

34. Hoy SM. Palovarotene: First Approval. Drugs. 2022 Apr. 82 (6):711-716. [QxMD MEDLINE Link].

35. Hsiao EC, Di Rocco M, Cali A, Zasloff M, Al Mukaddam M, Pignolo RJ, et al. Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP). Br J Clin Pharmacol. 2019 Jun. 85 (6):1199-1207. [QxMD MEDLINE Link].

36. Peng K, Cheung K, Lee A, Sieberg C, Borsook D, Upadhyay J. Longitudinal Evaluation of Pain, Flare-Up, and Emotional Health in Fibrodysplasia Ossificans Progressiva: Analyses of the International FOP Registry. JBMR Plus. 2019 Aug. 3 (8):e10181. [QxMD MEDLINE Link].

37. Dzukou T, Barbier C, Spyckerelle C, Labarriere F, Vittu G, Kremp O. [Fibrodysplasia ossificans progressiva in children. The interest of early diagnosis and treatment]. Presse Med. 2005 Mar 12. 34(5):373-7. [QxMD MEDLINE Link].

38. Pignolo RJ, Hsiao EC, Al Mukaddam M, Baujat G, Berglund SK, Brown MA, et al. Reduction of New Heterotopic Ossification (HO) in the Open-Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP). J Bone Miner Res. 2023 Mar. 38 (3):381-394. [QxMD MEDLINE Link]. [Full Text].

39. Matsuo K, Chavez RD, Barruet E, Hsiao EC. Inflammation in Fibrodysplasia Ossificans Progressiva and Other Forms of Heterotopic Ossification. Curr Osteoporos Rep. 2019 Dec. 17 (6):387-394. [QxMD MEDLINE Link].

40. Kaplan FS, Glaser DL, Pignolo RJ, Shore EM. A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton. Expert Opin Biol Ther. 2007 May. 7(5):705-12. [QxMD MEDLINE Link].

41. Kaplan FS, Le Merrer M, Glaser DL, et al. Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheumatol. 2008 Mar. 22(1):191-205. [QxMD MEDLINE Link]. [Full Text].

42. Palhares DB, Nascimento DR, Palhares MG, Lopes S, de L, Cristhina P, et al. Propranolol and ascorbic acid in control of fibrodysplasia ossificans progressiva flare-ups due to accidental falls. Intractable Rare Dis Res. 2019 Feb. 8 (1):24-28. [QxMD MEDLINE Link].

43. Clinical Trials Committee of the International Clinical Council on FOP (ICC). A message from the ICC on FOPCon. International Fibrodysplasia Ossificans Progressiva Association. Available at https://www.ifopa.org/icc_on_fopcon_therapy. May 24, 2019; Accessed: September 13, 2019.

44. Kaplan FS, Al Mukaddam M, Baujat G, et al. Emergency medical information and treatment guidelines for medical professionals. International Fibrodysplasia Ossificans Progressiva Association. Available at https://www.ifopa.org/for_medical_professionals. June 2019; Accessed: September 13, 2019.

45. Wadenya R, Fulcher M, Grunwald T, Nussbaum B, Grunwald Z. A description of two surgical and anesthetic management techniques used for a patient with fibrodysplasia ossificans progressiva. Spec Care Dentist. 2010 May. 30(3):106-9. [QxMD MEDLINE Link].

46. Kilmartin E, Grunwald Z, Kaplan FS, Nussbaum BL. General anesthesia for dental procedures in patients with fibrodysplasia ossificans progressiva: a review of 42 cases in 30 patients. Anesth Analg. 2014 Feb. 118(2):298-301. [QxMD MEDLINE Link].

47. Wentworth KL, Masharani U, Hsiao EC. Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva. Br J Clin Pharmacol. 2019 Jun. 85 (6):1180-1187. [QxMD MEDLINE Link].

48. Shaikh U, Khan A, Kumari P, Ishfaq A, Ekhator C, Yousuf P, et al. Novel Therapeutic Targets for Fibrodysplasia Ossificans Progressiva: Emerging Strategies and Future Directions. Cureus. 2023 Jul. 15 (7):e42614. [QxMD MEDLINE Link]. [Full Text].

49. Cappato S, Giacopelli F, Ravazzolo R, Bocciardi R. The Horizon of a Therapy for Rare Genetic Diseases: A "Druggable" Future for Fibrodysplasia Ossificans Progressiva. Int J Mol Sci. 2018 Mar 26. 19 (4):[QxMD MEDLINE Link].

50. Altschuler EL. Consideration of Rituximab for fibrodysplasia ossificans progressiva. Med Hypotheses. 2004. 63(3):407-8. [QxMD MEDLINE Link].

51. Alexander KA, Tseng HW, Fleming W, Jose B, Salga M, Kulina I, et al. Inhibition of JAK1/2 Tyrosine Kinases Reduces Neurogenic Heterotopic Ossification After Spinal Cord Injury. Front Immunol. 2019. 10:377. [QxMD MEDLINE Link].

Robert A Schwartz, MD, MPH Professor and Head of Dermatology, Professor of Pathology, Professor of Pediatrics, Professor of Medicine, Rutgers New Jersey Medical School

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, New York Academy of Medicine, Royal College of Physicians of Edinburgh, Sigma Xi, The Scientific Research Honor Society

Disclosure: Nothing to disclose.

Slawomir Majewski, MD Professor and Director, Department of Dermatology and Venereology, Warsaw School of Medicine, Poland

Disclosure: Nothing to disclose.

David F Butler, MD Former Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic

David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, Association of Military Dermatologists, Phi Beta Kappa, Texas Dermatological Society

Disclosure: Nothing to disclose.

Jeffrey J Miller, MD Associate Professor of Dermatology, Pennsylvania State University College of Medicine; Staff Dermatologist, Pennsylvania State Milton S Hershey Medical Center

Jeffrey J Miller, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, Society for Investigative Dermatology, Association of Professors of Dermatology, North American Hair Research Society

Disclosure: Nothing to disclose.

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Jean Paul Ortonne, MD Chair, Department of Dermatology, Professor, Hospital L'Archet, Nice University, France

Jean Paul Ortonne, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Sebastian S Majewski †

Disclosure: Nothing to disclose.

Stefania Jablonska, MD † Former Chairman, Professor Emeritus, Department of Dermatology, Warsaw School of Medicine, Poland

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article